{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/68c7da9e5819338468bb76fe/68cbed1d1e70111cd565374a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Rethinking Preclinical Testing – The DART Advantage","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/68c7da9e5819338468bb76fe/1758206031925-5133f667-3a87-4e4d-a2c6-3e9e98a2cd99.jpeg?height=200","description":"<p>What if you could rethink preclinical testing — beyond animal models, beyond limitations? Join us for the first episode of our podcast, \"<strong>Rethinking Preclinical Testing – The DART Advantage,</strong>\" featuring <strong>Dr. Subhadra Dravida, Founder &amp; CEO, Transcell Biologics</strong>, as the guest speaker, in a powerful conversation with our host, <strong>Barinder Marhok, Global Head – Healthcare &amp; Life Sciences, Quantiphi</strong>. Discover the Phi Moment – the breakthrough realization that led to <strong>DART</strong>, an AI-powered, stem cell-based platform that's rewriting the future of preclinical testing: faster, scalable, and more ethical.</p>","author_name":"Quantiphi"}